Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults

Published:2023-07-27 Issue:15 Volume:24 Page:1703-1713
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Mersin Sinan¹^ORCID,Gülük Fatih²,Gülcan Emirhan³,Eşkazan Ahmet Emre⁴^ORCID

Affiliation:

1. Department of Hematology, Dr. Ersin Arslan Training and Research Hospital, Gaziantep, Turkey

2. Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

3. Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey

4. Division of Hematology, Department of Internal Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2023.2240702

Reference97 articles.

1. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring

2. Cancer statistics, 2023

3. Molecular biology of chronic myeloid leukemia

4. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

5. First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP